The protein products from AGR2 [16, 23–25], CEAMAN6 [26–28], GNMT [29, 30], PDIA2 [31, 32], POSTN [17, 33, 34], RBPJL [35, 36] and S100P [37–39] have been reported as potential diagnostic and prognostic biomarkers for pancreatic cancer or have demonstrated to be involved in either pancreatic cancer, initiation, migration, invasion, metastasis, or chemoresistance. Here, AGR2 is linked to familial pancreatic carcinoma.